PDS Biotechnology (PDSB) Projected to Post Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

PDS Biotechnology Trading Up 0.8%

Shares of PDS Biotechnology stock opened at $0.72 on Wednesday. The stock has a market cap of $40.26 million, a P/E ratio of -1.07 and a beta of 1.62. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.55. The business’s 50 day moving average is $0.88 and its 200-day moving average is $0.88.

Analyst Upgrades and Downgrades

PDSB has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of PDS Biotechnology in a report on Wednesday, April 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. Finally, Wall Street Zen lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Investors Weigh In On PDS Biotechnology

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $25,000. Armistice Capital LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth approximately $2,182,000. Commonwealth Equity Services LLC boosted its stake in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the period. Geode Capital Management LLC boosted its stake in PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after purchasing an additional 38,399 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after buying an additional 80,937 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.